Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
View Patent ↗A method is provided for increasing the permeability of skin or mucosal tissue to transdermally administered nonsteroidal anti-inflammatory drugs (NSAIDs). The method involves use of a specified amount of a hydroxide-releasing agent, the amount optimized to increase the flux of the NSAID through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. Formulations and drug delivery systems for co-administering a hydroxide-releasing agent with an NSAID are provided as well.
1. A composition of matter useful for the delivery of a nonsteroidal anti-inflammatory drug through a body surface, comprising a formulation comprising: (a) a therapeutically effective amount of a nonsteroidal anti-inflammatory drug; (b) a hydroxide-releasing agent in an amount effective to enhance the flux of the drug through the body surface without causing damage thereto and effective to provide a pH in the range of approximately 8.0 to 13 at the body surface, during drug administration; and wherein the amount of hydroxide-releasing agent in the formulation is the total of (a) the amount required to neutralize any acidic species in the formulation plus (b) an amount equal to approximately 0.5 to 25.0 wt % of the formulation; and (c) a pharmaceutically acceptable carrier suitable for topical or transdermal drug administration, wherein:
the composition is provided in a transdermal patch comprising a laminated structure that is to be affixed to the skin, the structure comprising a drug reservoir comprising the formulation contained within a polymeric matrix of a pharmaceutically acceptable adhesive material that serves to affix the system to the skin during drug delivery, and wherein the hydroxide-releasing agent comprises an inorganic hydroxide selected from the group consisting of sodium hydroxide and potassium hydroxide.
2. The composition of claim 1 , wherein the pH at the body surface is in the range of approximately 8.0 to 11.5.
3. The composition of claim 2 , wherein the pH at the body surface is in the range of approximately 8.5 to 11.5.
4. The composition of claim 1 , wherein the carrier is aqueous.
5. The composition of claim 1 , wherein the composition is free of additional permeation enhancers.
6. The composition of claim 1 , wherein the composition is free of organic solvents.
7. The composition of claim 1 , wherein the hydroxide-releasing agent releases free hydroxide ions in the presence of an aqueous fluid.
8. The composition of claim 1 , wherein the amount of inorganic hydroxide in the formulation is the total of
(a) the amount required to neutralize any acidic species in the formulation plus
(b) an amount equal to approximately 0.5 wt % to 4.0 wt % of the formulation.
9. The composition of claim 1 , wherein the drug is systemically acting.
10. The composition of claim 1 , wherein the drug is a propionic acid derivative.
11. The composition of claim 10 , wherein the propionic acid derivative is selected from the group consisting of ketoprofen, flurbiprofen, ibuprofen, naproxen, fenoprofen, benoxaprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, suprofen, alminoprofen, butibufen, fenbufen, tiaprofenic acid, salts, esters, amides of any of the foregoing, and combinations thereof.
12. The composition of claim 11 , wherein the propionic acid derivative is selected from the group consisting of ketoprofen and ibuprofen.
13. The composition of claim 1 , wherein the drug is selected from the group consisting of acetylsalicylic acid, apazone, diclofenac, difenpiramide, diflunisal, etodolac, flufenamic acid, indomethacin, ketorolac, meclofenamate, mefenamic acid, nabumetone, phenylbutazone, piroxicam, salicylic acid, sulindac, tolmetin, salts, esters, amides of any of the foregoing, and combinations thereof.
14. The composition of claim 13 , wherein the drug is selected from the group consisting of diclofenac, ketorolac, and piroxicam.
15. A system for the topical or transdermal administration of a nonsteroidal anti inflammatory drug, comprising: (a) at least one drug reservoir containing the drug and a hydroxide-releasing agent in an amount effective to enhance the flux of the drug through the body surface without causing damage thereto and effective to provide a pH in the range of approximately 8.0 to 13 at the body surface during drug administration; and wherein the amount of hydroxide-releasing agent in the reservoir is the total of (a) the amount required to neutralize any acidic species in the reservoir plus (b) an amount equal to approximately 0.5 to 25.0 wt % of the reservoir; (b) a means for maintaining the system in drug and enhancer transmitting relationship to the body surface; and (c) a backing layer that serves as the outer surface of the system during use, wherein the drug reservoir is comprised of a polymeric adhesive, wherein the hydroxide-releasing agent comprises an inorganic hydroxide selected from the group consisting of sodium hydroxide and potassium hydroxide.
16. The system of claim 15 , wherein the pH at the body surface is in the range of approximately 8.0 to 11.5.
17. The system of claim 16 , wherein the pH at the body surface is in the range of approximately 8.5 to 11.5.
18. The system of claim 15 , wherein the backing layer is occlusive.
19. The system of claim 15 , wherein the polymeric adhesive serves as the means for maintaining the system in drug and enhancer transmitting relationship to the body service.
20. The system of claim 15 , wherein the drug is systemically acting.
21. The system of claim 15 , wherein the drug is a propionic acid derivative.
22. The system of claim 21 , wherein the propionic acid derivative is selected from the group consisting of ketoprofen, flurbiprofen, ibuprofen, naproxen, fenoprofen, benoxaprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, suprofen, alminoprofen, butibufen, fenbufen, tiaprofenic acid, salts, esters, amides of any of the foregoing, and combinations thereof.
23. The system of claim 22 , wherein the propionic acid derivative is selected from the group consisting of ketoprofen and ibuprofen.
24. The system of claim 15 , wherein the drug is selected from the group consisting of acetylsalicylic acid, apazone, diclofenac, difenpiramide, diflunisal, etodolac, flufenamic acid, indomethacin, ketorolac, meclofenamate, mefenamic acid, nabumetone, phenylbutazone, piroxicam, salicylic acid, sulindac, tolmetin, salts, esters, amides of any of the foregoing, and combinations thereof.
25. The system of claim 24 , wherein the drug is selected from the group consisting of diclofenac, ketorolac, and piroxicam.
26. A composition according to claim 1 wherein the adhesive comprises a pressure-sensitive adhesive (PSA) that is suitable for long-term skin contact, and that is physically and chemically compatible with the active agent and hydroxide-releasing agent.
27. A composition according to claim 26 wherein the adhesive comprises polyisobutylene.
28. A composition according to claim 26 wherein the patch is adapted to deliver the drug through a defined area of intact unbroken living skin or mucosal tissue having an area of about 20 cm 2 to about 60 cm 2 .
29. A composition according to claim 26 wherein the flux of the active agent through the body surface is increased relative to the rate that would be obtained in the absence of permeation enhancement, and the nonsteroidal anti-inflammatory drug permeates through the body surface of a patient, without causing damage thereto.
30. A composition according to claim 29 wherein the hydroxide-releasing agent represents about 0.5 wt % to 3.0 wt % of the formulation, and the concentration of the active agent in the formulation is between about 5 wt % to 20 wt % of the weight of the polymeric matrix.
31. A composition according to claim 30 wherein the patch further comprises a flexible elastomeric backing layer that functions as the primary structural element of the transdermal system and provides the device with flexibility and occlusivity, the backing layer being inert and incapable of absorbing drug, hydroxide-releasing agent, or components of the formulation contained within the device, and that permits the device to follow the contours of the skin and be worn comfortably on areas of skin such as at joints or other points of flexure.
32. A composition according to claim 31 wherein the backing layer is formed from a synthetic polymer selected from the group consisting of polyester, polyethylene, polypropylene, polyurethane, polyvinylidine chloride, polyether amide, natural polymers, and macroporous woven and nonwoven materials.
33. A composition according to claim 1 wherein the adhesive material comprises polyisobutylene.
34. A composition according to claim 1 wherein the patch is adapted to deliver the drug through a defined area of intact unbroken living skin or mucosal tissue having an area of about 20 cm 2 to about 60 cm 2 .
35. A composition according to claim 1 wherein the flux of the active agent through the body surface is increased relative to the rate that would be obtained in the absence of permeation enhancement, and the nonsteroidal anti-inflammatory drug permeates through the body surface of a patient, without causing damage thereto.
36. A composition according to claim 1 wherein the hydroxide-releasing agent represents about 0.5 wt % to 3.0 wt % of the formulation, and the concentration of the active agent in the formulation is between about 5 wt % to 20 wt % of the weight of the polymeric matrix.
37. A composition according to claim 1 wherein the patch further comprises a flexible elastomeric backing layer.
38. A composition according to claim 37 wherein the backing layer is formed from a synthetic polymer selected from the group consisting of polyester, polyethylene, polypropylene, polyurethane, polyvinylidine chloride, polyether amide, natural polymers, and macroporous woven and nonwoven materials.
39. A system according to claim 15 wherein the polymeric adhesive comprises polyisobutylene.
40. A system according to claim 15 wherein the patch is adapted to deliver the drug through a defined area of intact unbroken living skin or mucosal tissue having an area of about 20 cm 2 to about 60 cm 2 .
41. A system according to claim 15 wherein the flux of the active agent through the body surface is increased relative to the rate that would be obtained in the absence of permeation enhancement, and the nonsteroidal anti-inflammatory drug permeates through the body surface of a patient, without causing damage thereto.
42. A system according to claim 15 wherein the hydroxide-releasing agent represents about 0.5 wt % to 3.0 wt % of the formulation, and the concentration of the active agent in the formulation is between about 5 wt % to 20 wt % of the weight of the polymeric matrix.
43. A system according to claim 15 wherein the patch further comprises a flexible elastomeric backing layer that functions as the primary structural element of the transdermal system and provides the device with flexibility and occlusivity, the backing layer being inert and incapable of absorbing drug, hydroxide-releasing agent, or components of the formulation contained within the device, and that permits the device to follow the contours of the skin and be worn comfortably on areas of skin such as at joints or other points of flexure.
44. A system according to claim 15 wherein the backing layer is formed from a synthetic polymer selected from the group consisting of polyester, polyethylene, polypropylene, polyurethane, polyvinylidine chloride, and polyether amide, natural polymers, and macroporous woven and nonwoven materials.